Delineating the Contribution of Secretory Transporters in the Efflux of Etoposide Using Madin-Darby Canine Kidney (MDCK) Cells Overexpressing P-Glycoprotein (Pgp), Multidrug Resistance-Associated Protein (MRP1), and Canalicular Multispecific Organic Anion Transporter (cMOAT)
- 1 April 2002
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 30 (4) , 457-463
- https://doi.org/10.1124/dmd.30.4.457
Abstract
Multidrug resistance conferred to cancer cells is often mediated by the expression of efflux transporter “pumps”. It is also believed that many of the same transporters are involved in drug efflux from numerous normal endothelial and epithelial cell types in the intestine, brain, kidney, and liver. Etoposide transport kinetics were characterized in Caco-2 cells and in well established Madin-Darby canine kidney (MDCKII) cell lines that were stably-transfected with a human cDNA encoding P-glycoprotein (Pgp), human multidrug resistance protein (MRP1), or the canalicular multispecific organic anion (cMOAT) transporters to determine the roles of these transporters in etoposide efflux. Etoposide transport kinetics were concentration-dependent in the MDCKII-MDR1 and MDCKII-cMOAT cells. The apparent secretory Michaelis constant (Km) and carrier-mediated permeability (Pc) values for Pgp and cMOAT were 254.96 ± 94.39 μM and 5.96 ± 0.41 × 10−6 cm/s and 616.54 ± 163.15 μM and 1.87 ± 0.10 × 10−5 cm/s, respectively. The secretory permeability of etoposide decreased significantly in the basal to apical (B to A) (i.e., efflux) direction, whereas the permeability increased 2.3-fold in the apical to basal (A to B) direction in MDCKII-MDR1 cells in the presence of elacridar (GF120918). Moderate inhibition of etoposide efflux by leukotriene C4 (LTC4) was observed in MDCKII-cMOAT cells. Furthermore, etoposide inhibited LTC4efflux, confirming the involvement of cMOAT. The flux of etoposide in MDCKII-MRP1 cells was similar to that in MDCKII/wt control cells. The current results demonstrate that the secretory transport mechanism of etoposide involves multiple transporters, including Pgp and cMOAT but not MRP1. These results demonstrate that Pgp and cMOAT are involved in the intestinal secretory transport of etoposide. Since the intestinal secretion of etoposide was previously reported in the literature, it also suggests that they may be involved in the in vivo intestinal secretion of etoposide; however, mechanistic in vivo studies are required to confirm this.This publication has 37 references indexed in Scilit:
- A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutantsPublished by Elsevier ,2003
- MDCK (Madin-Darby Canine Kidney) Cells: A Tool for Membrane Permeability ScreeningJournal of Pharmaceutical Sciences, 1999
- Enhancement of glucuronosyl etoposide transport by glutathione in multidrug resistance-associated protein-overexpressing cellsCancer Letters, 1998
- Different Pattern of MRP Localization in Ciliated and Basal Cells from Human Bronchial EpitheliumJournal of Histochemistry & Cytochemistry, 1998
- Drug export activity of the human canalicular multispecific organic anion transporter in polarized kidney MDCK cells expressing cMOAT (MRP2) cDNA.Journal of Clinical Investigation, 1998
- A mutation in the human canalicular multispecific organic anion transporter gene causes the Dubin-Johnson syndromeHepatology, 1997
- Expression of the MRP gene-encoded conjugate export pump in liver and its selective absence from the canalicular membrane in transport-deficient mutant hepatocytes.The Journal of cell biology, 1995
- BIOCHEMISTRY OF MULTIDRUG RESISTANCE MEDIATED BY THE MULTIDRUG TRANSPORTERAnnual Review of Biochemistry, 1993
- Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell LineScience, 1992
- Etoposide (VP-16–213)New England Journal of Medicine, 1985